Navigation Links
Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
Date:6/11/2008

LONDON, June 11 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes a steroid comparator arm.

The study will evaluate the safety, tolerability, and preliminary efficacy of intranasal MRX-4 in AR patients outside of allergy season as compared with both placebo and an intranasal steroid. An experimental multi-functional anti-inflammatory drug (MFAID), MRX-4 is a non-steroidal potential treatment for AR that was shown to be safe and well tolerated in a Phase I equivalent trial completed in Israel earlier this year.

"This study will provide valuable data regarding its potential in allergic rhinitis, including efficacy, tolerability and pharmacokinetic data," said Dr. Yuval Cohen, president of Morria. "We are excited to be taking this significant step toward testing a potentially safer, more effective, and more affordable treatment option for the significant commercial opportunity in the multi-billion dollar allergic rhinitis market".

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals termed multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combine
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
2. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...Newswire-Asia/ -- ScinoPharm, a leading global,sup... announced that its,Tainan facility has received t...ridge(R) Consultants, Inc. The Certification confi... safe handling of potent active,pharmaceutical ing...ies and,production areas used for the manufacturin...
(Date:11/19/2009)...wswire/ -- Ligon Discovery, Inc., which uses propr...d drugs against high-value targets, today announce...incTANK Ventures. The company will use the capital...ill screen over 100 high-value disease protein tar...al Partner Christian Bailey joins the board. ,,...
(Date:11/19/2009)...swire/ -- Breast-Specific Gamma Imaging/Molecular ...endorsed by two highly esteemed organizations for ...east Imaging (SBI) and the American College of Sur...g the further application of this breakthrough ima...cancer. ,, "These endorsements reinforce what I...
Breaking Medicine Technology:ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 3Sundia Welcomes Professional U S Delegation 14469 1Sundia Welcomes Professional U S Delegation 14469 2Beneficial effects of alcohol 3F 59447 1Beneficial effects of alcohol 3F 59447 2Cell study explains why younger people more at risk of vCJD 10351 1Cell study explains why younger people more at risk of vCJD 10351 2
(Date:11/22/2009)...YORK (Nov. 22 2009) -- Physician-scientists from W...ecular mechanism that may prove to be a powerful t... a type of cancer that affects lymphocytes, or whi...archers have been able to powerfully suppress tumo..., Promising results have led to the design of a c...
(Date:11/22/2009)... Man & Machine post You Tub...sus the competition , Lan...yboard users interested in learning what a really ...une into “Really Cool Keyboard vs Washable C... The film demonstrates how the premium, Really Coo...
(Date:11/21/2009)... , NEW YORK, Nov. 21 Milvia Lop...w York City, recently filed suit, in Supreme Court...e complaint alleges that while Ms. Lopez underwent...at ST. VINCENT,S HOSPITAL , doctors used an HIV i...plaint alleges that several hours after being disc...
(Date:11/21/2009)... Innovative medical apparel com...rence , San Clemente, Cal...ker of breakthrough medical apparel, today announc... display at Medica 2009, a leading international t...orf, Germany. Medelita inaugurates its men,s colle...
(Date:11/20/2009)..., Pioneering Neurologist Closer to Understandin... 20 Dr. Jeremy Schmahma...ol and neurologist at the Massachusetts General Ho...ted his laboratory,s research on the new field of ...INDlink Foundation. ,, Dr. Schmahmann is an awa...
Breaking Medicine News(10 mins):Health News:New cancer target for non-Hodgkin's lymphoma 2Health News:Waterproof, Cleanable Computer Keyboard Video Comparison Now Available on You Tube 2Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2
...oration and Roush Fenway Racing;,Launches New Inte...N, April 21 The American Red Cross,today announce...ampaign to,recruit NASCAR fans as blood donors and.../DC20034 ), Through the support of 3M and Roush ...
...rwin,Professional Underwriters, Inc. (Darwin) (NYS...e its first quarter 2008 financial results on Mond...the company,s first quarter,2008 financial results...ve webcast of Darwin,s earnings conference call ca...
...Pharmaceuticals, Inc. (Nasdaq: ISTA ), today anno... results on April 30, 2008, after the U.S. markets...imultaneous webcast, to,discuss these results at 4...nts may dial 617-597-5397. The,access code for the...
... their scalp or neck appear less likely to survive...other sites, according to a report in the April is...chives journals. , Melanoma rates continue to inc...g cancer prognosis has been debated for decades, t...
...ecisions on Bottom Line Return at 3rd Annual ... NEW YORK and LONDON, April 21 Dr. Andree Bates,p...ularis, will be,delivering a presentation on Makin...8-0421-ABates_72dpi.jpg) *(Photo Caption: Dr. And...
...isolate electrical impulses causing irregular hear...) -- Adding one step and no more than 20 seconds t... an operation to treat the common irregular heartb...ns at Washington University School of Medicine in ...
Other Medicine News:Health News:American Red Cross Launches National Campaign to Connect NASCAR Fans With Blood Donations 2Health News:American Red Cross Launches National Campaign to Connect NASCAR Fans With Blood Donations 3Health News:Darwin to Announce First Quarter 2008 Financial Results 2Health News:Survival rates appear lower for scalp and neck melanoma than for other sites 2Health News:Eularis to Address Making the Right Research Decision for ROI 2Health News:New Atrial Fibrillation Surgery Improves Results 2
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
Medicine Products: